Acquisition of Laprolan B.V. from Fornix BioSciences N.V. (Details) (Laprolan B.V.)	3 Months Ended	12 Months Ended
	Jun. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Sep. 30, 2010 USD ($)	Sep. 30, 2012 USD ($)	Jan. 01, 2011 USD ($)	Jan. 01, 2011 EUR (€)
Acquisition of Laprolan B.V. from Fornix BioSciences N.V.
Purchase price paid to Fornix					$ 15,057,775	€ 10,474,974
Purchase price paid in cash					60,217
Interest paid					119,433
Goodwill acquired				5,602,000
Finite-lived intangibles acquired				5,612,000
Reduction in goodwill and deferred tax liabilities	669,000
Fair values of the assets and liabilities acquired
Current assets				3,212,000
Property and equipment				1,831,000
Intangible assets				10,545,000
Total assets acquired				15,588,000
Current liabilities				824,000
Long term liabilities				877,000
Total liabilities assumed				1,701,000
Pro forma unaudited results of operations
Net sales		55,633,000	52,767,000
Net loss		(159,000)	2,356,000
Per share data:
Basic loss (in dollars per share)		$ (0.01)	$ 0.19
Diluted loss (in dollars per share)		$ (0.01)	$ 0.18
Decrease in net loss for one-time merger and acquisition costs		725,000
Decrease in net loss related to a short term accounting and IT support contract		$ 45,000